- Home
- CAPR vs VERV Comparison
CAPR vs VERV Comparison
Compare CAPR & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- VERV
- Stock Information
- Founded
- CAPR 2005
- VERV 2018
- Country
- CAPR United States
- VERV United States
- Employees
- CAPR N/A
- VERV N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- VERV Medicinal Chemicals and Botanical Products
- Sector
- CAPR Health Care
- VERV Health Care
- Exchange
- CAPR Nasdaq
- VERV Nasdaq
- Market Cap
- CAPR 622.9M
- VERV 475.0M
- IPO Year
- CAPR N/A
- VERV 2021
- Fundamental
- Price
- CAPR $12.79
- VERV $6.15
- Analyst Decision
- CAPR Strong Buy
- VERV Strong Buy
- Analyst Count
- CAPR 7
- VERV 4
- Target Price
- CAPR $39.29
- VERV $25.50
- AVG Volume (30 Days)
- CAPR 1.5M
- VERV 1.4M
- Earning Date
- CAPR 03-19-2025
- VERV 05-07-2025
- Dividend Yield
- CAPR N/A
- VERV N/A
- EPS Growth
- CAPR N/A
- VERV N/A
- EPS
- CAPR N/A
- VERV N/A
- Revenue
- CAPR $23,228,045.00
- VERV $32,332,000.00
- Revenue This Year
- CAPR N/A
- VERV N/A
- Revenue Next Year
- CAPR $74.85
- VERV N/A
- P/E Ratio
- CAPR N/A
- VERV N/A
- Revenue Growth
- CAPR 65.33
- VERV 174.98
- 52 Week Low
- CAPR $3.52
- VERV $4.31
- 52 Week High
- CAPR $23.40
- VERV $14.30
- Technical
- Relative Strength Index (RSI)
- CAPR 42.76
- VERV 41.76
- Support Level
- CAPR $11.75
- VERV $5.57
- Resistance Level
- CAPR $16.17
- VERV $6.61
- Average True Range (ATR)
- CAPR 1.51
- VERV 0.57
- MACD
- CAPR -0.18
- VERV -0.07
- Stochastic Oscillator
- CAPR 22.96
- VERV 32.37
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.